What Mevia does

Mevia is a Gothenburg-based, privately-held company founded in 2014 as a spin-off from Chalmers Technical University, providing IoT-enabled medication adherence solutions for clinical trials, patient support programs, and municipal elderly care. Its product line consists of two cellular-connected hardware devices — Mepill for pill-blisters and Medose for multi-dose dispensers — that detect dose extraction in real time via conductive trace monitoring and transmit data over global cellular networks using integrated roaming SIM cards. These feed a digital analytics dashboard and a multi-platform patient application (iOS, Android, Web, branded Mevia GO and Mevia PRO), with optional SMS-to-Web setup for patients without smartphones and APIs for integration into CRO/IWRS systems.

The business model combines hardware device sales/leasing, software/dashboard subscriptions, and clinical trial services delivered end-to-end (protocol adaptation, packaging customisation, deployment, monitoring, collection, data transfer). The company sells quote-based, multi-year contracts to pharmaceutical and life science customers via enterprise field sales, while evaluation/demo units (Mepill Intro, Medose Intro) are offered through an e-commerce storefront. Named enterprise customers include Merck KGaA (flagship global multicentre study), with technology integrations through AARDEX Group (2023) and a major global CRO (2020), and a healthcare packaging partnership with Jones Healthcare Group (2017) for North American and European distribution. Swedish municipalities (Skellefteå, Kiruna, Orust) deploy Mevia IoT devices for elderly home medication management. Pricing is not publicly disclosed.

Mevia is founder-led (CEO Jesper Hassel, CTO Jesper Lugner) with a small team (1–10 employees) and has raised approximately $3.6M in disclosed venture funding from Chalmers Ventures AB (lead across all rounds) and Almi Invest. The company emphasises sustainability (reusable devices, no single-use electronics, paper-based packaging) and validated outcomes, including a reduction in medical deviations from 60% to 14% over a 3-month home care study and 87% adherence in an over-80 cohort pilot.

Name

Mevia

Legal name

Mevia

Website

https://mevia.se

Company type

Private

Founded year

2014

Operating status

Operating

Headcount range

1–10 employees

Short description

Mevia builds IoT-enabled, cellular-connected medication adherence hardware (Mepill, Medose) and supporting dashboard and mobile applications, sold to pharmaceutical companies running clinical trials and patient support programs, with additional municipal elderly-care deployments in Sweden.

Ownership category

akta.pro rank

Product category

Medication Adherence Technology

NAICS

Home Health Care Services (62161), Ambulatory Health Care Services (621), Other Ambulatory Health Care Services (6219)

SIC

Services-Home Health Care Services (8082)

akta.pro primary industry

Medication Adherence & Smart Drug Delivery (Connected Inhalers, Pens, Pill Dispensers) (HLACAPAH)

akta.pro secondary industries

Remote Adherence Monitoring & Smart Dispenser Services (HSABALAI), Patient App, Adherence & Engagement for RPM Programs (HLACAFAJ), Medication Adherence, Reminders & Patient Support (HLACAKAF)

Keywords

• Medication adherence solutions
• Clinical trial adherence monitoring
• IoT adherence devices
• Patient support programs
• Cellular smart packaging

Headquarters

HQ city

Gothenburg

HQ country

Sweden

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Supply Chain, Marketing or Sales, Operations

Revenue model

1. Hardware Device Sales / Lease: Mevia offers its hardware devices (Mepill and Medose) which are reusable cellular adherence monitoring devices. Devices are sold as part of bundled solutions including 3-month trial licenses (for evaluation) and full program deployments for clinical trials and patient support programs. Devices are described as reusable, with collection and reuse/recycling at end of program.
2. Software Subscription (Dashboard & App): The digital dashboard and mobile/web applications (Mevia GO and Mevia Pro) are provided as part of the end-to-end solution, likely on a subscription basis tied to device deployment and user counts. The solution is described as supporting clinical trial data management with safe data handling and customisable reporting.
3. License Fees (3-Month Trial License): Mepill Intro and Medose Intro packages include a 3-month valid license to test the solution, indicating a time-limited license model for evaluation purposes.
4. Clinical Trial Services: Mevia provides end-to-end services for clinical trials including preparatory phase (protocol adaptation, packaging customisation, device distribution), execution phase (patient introduction, real-time monitoring, device maintenance), and evaluation phase (device collection, safe data transfer to IWRS, research validation). Revenue derived from service delivery in partnership with life science companies.

Pricing tiers

Go-to-market motion2 records

Distribution channels4 records

Marketing channels5 records

Core offering

Mevia provides a customized end-to-end real-time medication adherence solution for clinical trials and patient support programs. The solution comprises reusable cellular IoT hardware devices (Mepill for pill-blisters and Medose for dose-dispensers) that detect pill or dose extraction in real time and transmit data over cellular networks, a Data Analytic Dashboard for monitoring adherence behavior, and patient-facing iOS, Android, and Web applications with SMS reminders and health data collection.

Product overview

Mevia is a Gothenburg-based company offering a customizable end-to-end medication adherence solution. The portfolio consists of two core hardware products (Mepill for pill-blisters and Medose for dose-dispensers), a Data Analytic Dashboard for real-time adherence monitoring, and a multi-platform Application (iOS, Android, Web) with Mevia PRO and Mevia GO variants. These can be purchased as individual solutions (Hardware Adherence Solution or Digital Adherence Solution) or combined as The Full End-to-end Solution. The system enables real-time medication adherence monitoring in clinical trials and patient support programs, with cellular device data automatically synced to the dashboard and application, and SMS/Web notifications for patient support.

Differentiator

Problem solved

Functional benefit

Brands

• Mepill: A reusable cellular device for pill-blisters that detects when a pill is extracted in real-time. Designed as a sustainable option for smart packaging with no single-use electronics.
• Medose
• Mevia Dashboard

Products and services

• Mepill Reusable cellular IoT device for pill-blisters that detects when a pill is extracted in real time via conductive trace monitoring and transmits data globally via an integrated roaming SIM card. Monitors 28 pills across one or several blisters, includes child safety and tamper evidence features, and uses 100% paper-based packaging with no single-use electronics or batteries. Designed for pharmaceutical clinical trials, patient support programs, and elderly home medication management.
• Medose Reusable cellular IoT device for dose-dispensers that detects when a dose with multiple pills is extracted in real time. Supports 28 dose cavities that can be filled by pharmacy or CMO (automated or manually), includes an integrated roaming SIM card for global data transmission, and updates users via e-ink display, LED light, application, and SMS. Designed for clinical trials, patient support programs, and elderly home medication management.
• Data Analytic Dashboard Digital dashboard providing real-time adherence data from multiple sources (Mepill, Medose). Allows administrative users to follow up on adherence behaviors, identify when extra counselling is needed, zoom in on patient details, and extract customized PDFs for accessible material sharing. Supports customizable dose schedules and reminders for clinical trial and patient support program administrators.
• Mevia Application (Mevia GO and Mevia PRO) iOS, Android, and Web application for treatment support, available as Mevia GO (patient variant) and Mevia PRO (professional variant). Features dose calendar, adherence tracking, manual or automatic dose logging, push notification and SMS reminders, health data collection (symptoms, food intake and other metrics), FAQs, guides, videos and tutorials, and customization including the customer's logo on the main screen.
• The Hardware Adherence Solution Bundled solution combining Mepill (for pill-blisters) and Medose (for dose-dispensers) hardware devices for organizations that have their own systems and want to integrate Mevia's hardware. Includes sustainable smart packaging with no single-use electronics, safe data handling, and API integration options. Sold on multi-year contracts via the Mevia e-commerce storefront.
• The Digital Adherence Solution Bundled software-only solution for organizations that already have their own hardware and want to integrate into Mevia's systems. Includes a customized-logo app for Android and iOS with full patient functionality, digital training materials, and Mevia dashboard with real-time adherence data. Sold on annual subscriptions.
• The Full End-to-end Solution Complete end-to-end bundled adherence solution combining Mepill and Medose hardware devices with Mevia Dashboard and Mevia Application, plus SMS integration for patient support. Includes real-time adherence data collection, digital dashboard, treatment support application, and customizable packaging, schedule, and reminder configuration. Sold via multi-year contracts.
• Mepill Intro (3-Month Trial License) Evaluation package including one Mepill device, a user instruction manual, and a 3-month valid license to test the adherence solution, sold via the Mevia e-commerce storefront as a pay-as-you-go one-time license for prospective clinical trial and patient support program buyers.

Quantifiable outcome

• 97-99% of pills consumed when taken out of a monitored package
• +4 more outcomes

Named customers6 records

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

Yes

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Partnerships

Nine partnerships are on record, tiered core and minor.

• AARDEX GroupcoreTechnology or Integration · 1 January 2023In 2023, Mevia partnered with Aardex to improve real-time adherence data by integrating Mevia's hardware into Aardex's platform. Aardex cited Mevia's unique and sustainable adherence hardware solution as an ideal enhancement to their real-time adherence data capabilities.
• Merck KGaAcoreStrategic or Co-development Partner · 1 January 2020Mevia is a trusted partner to Merck in a global multicentre clinical study where they support patient adherence and safe data management. This is a flagship reference customer relationship.
• Jones Healthcare GroupcoreStrategic or Co-development Partner · 1 January 2017Mevia entered a collaboration with Jones Healthcare Group in 2017, aiming to bring real-time adherence cards to North America and Europe. Jones Healthcare Group noted Mevia's collaborative and responsive approach enables them to improve products and services for customers and patients.
• Merck KGaAcoreStrategic or Co-development PartnerMevia is a trusted partner to Merck KGaA, Darmstadt, Germany in a global multicentre clinical study supporting patient adherence and safe data management.
• AARDEX Group - Medication Adherence ToolscoreTechnology or IntegrationAardex Group is a medication adherence tools company that partnered with Mevia to integrate Mevia's hardware into their platform, enhancing real-time adherence data quality.
• Jones Healthcare GroupcoreStrategic or Co-development PartnerJones Healthcare Group collaboration enables improvement of products and services for their customers and patients through Mevia's real-time adherence solution.
• Skellefteå KommunminorStrategic or Co-development PartnerMevia works with Skellefteå Kommun to assist individuals with medication management using IoT technologies, creating security and enabling older people to remain in their homes.
• Kiruna KommunminorStrategic or Co-development PartnerKiruna Kommun utilises Mevia's IoT-based medication management solution to foster security and enable older people to adhere to their medication schedules.
• Orust KommunminorStrategic or Co-development PartnerOrust Kommun uses Mevia's service to help individuals handle their medicine, with clear benefits for both staff and individuals.

Scale indicators9 records

Recent moves7 records

Expansion highlights5 records

Direct peers

• AARDEX Group: Provider of the leading MEMS-based real-time adherence data platform (including the widely used Medication Event Monitoring System) used across clinical trials; partnered with Mevia in 2023 to integrate Mevia's hardware into its analytics layer, making it the most directly comparable peer.
• AdhereTech: Developer of connected smart pill bottles that capture and transmit real-time adherence data, primarily to pharma patient support programs; directly comparable to Mevia in combining connected hardware with a dashboard/data service for adherence monitoring.
• MedMinder: Smart pill dispenser and pharmacy service focused on improving adherence for patients at home, especially in elderly and chronic care populations — overlaps Mevia's municipality/elderly segment and connected-dispenser model.
• Vaica Medical: Israel-based provider of IoT-connected smart medication dispensers and adherence software for clinical trials and patient support — directly comparable product category, customer base, and adherence data layer to Mevia.
• Hero Health: Smart in-home medication dispenser with reminders, real-time tracking, and a companion app for patients/families — comparable connected-dispenser consumer-to-patient experience and adherence value proposition.
• Medisafe: Digital medication-adherence platform (iOS/Android, web, content, EMR/EHR integrations) widely used in pharma PSPs — closely comparable to Mevia's app and dashboard layer, though software-only versus Mevia's hardware-plus-software stack.
• Spencer Health Solutions (formerly Compliance Meds Technologies): Connected medication management platform combining a smart in-home dispenser, patient app, and clinician portal for adherence and engagement — comparable end-to-end architecture and pharma/health-system buyers to Mevia.

Broad incumbents

• Propeller Health (ResMed): Connected inhaler sensors with a digital adherence platform acquired by ResMed; broader incumbent in connected drug-delivery adherence, useful as a comparator for IoT-adherence in a different drug-delivery modality.
• Koninklijke Philips (Medication Dispensing Service / Philips Lifeline): Large medtech incumbent offering connected medication dispensers and RPM services through its Lifeline and population-health portfolios; competes for the same elderly and chronic care buyer Mevia targets in the Nordic municipal segment.

Emerging players

• Catalia Health (Mabu health companion): Emerging player in digital patient engagement and adherence for chronic conditions with a connected health companion; intersects Mevia's PSP/CRM segment with a different (social-robot) delivery vehicle — adjacent benchmark for digital adherence players.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/meviatweets
• Facebookfacebook.com/meviasocial
• LinkedInlinkedin.com/company/mevia-ab

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Funding overview

Funding rounds6 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Mevia